Sugi Predict

Sugi Predict / Targets / NOTCH2

NOTCH2

Neurogenic locus notch homolog protein 2 · Q04721 · NOTCH2 on Sugi Atlas →

862 patent compounds predicted against NOTCH2, 767 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15622117 SCHEMBL15622117 1.00 1/20
SCHEMBL15622142 SCHEMBL15622142 1.00 1/20
SCHEMBL15622692 SCHEMBL15622692 0.91 1/20
SCHEMBL15622116 SCHEMBL15622116 0.89 1/20
SCHEMBL15622141 SCHEMBL15622141 0.89 1/20
SCHEMBL15621981 SCHEMBL15621981 0.89 1/20
SCHEMBL15622436 SCHEMBL15622436 0.89 1/20
Osugacestat Osugacestat (SCHEMBL12543867) 0.84 1/20
Osugacestat Osugacestat (SCHEMBL12543868) 0.84 1/20
Osugacestat Osugacestat (SCHEMBL15622455) 0.84 1/20
SCHEMBL12542524 SCHEMBL12542524 0.80 1/20
SCHEMBL12542526 SCHEMBL12542526 0.80 1/20
SCHEMBL12542944 SCHEMBL12542944 0.80 1/20
SCHEMBL12542945 SCHEMBL12542945 0.80 1/20
SCHEMBL12690166 SCHEMBL12690166 0.80 1/20
SCHEMBL15623717 SCHEMBL15623717 0.80 1/20
SCHEMBL15622372 SCHEMBL15622372 0.79 1/20
SCHEMBL12542696 SCHEMBL12542696 0.78 1/20
SCHEMBL12543029 SCHEMBL12543029 0.78 1/20
SCHEMBL12690189 SCHEMBL12690189 0.77 1/20

Clinical trials — most relevant to NOTCH2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer PHASE4COMPLETED
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer PHASE1/PHASE2WITHDRAWN
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis PHASE2COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma PHASE1/PHASE2COMPLETED
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery PHASE2WITHDRAWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
NG2 and DLL3 CAR-T Cells Targeting Melanoma PHASE1/PHASE2RECRUITING
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study) PHASE2COMPLETED
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer PHASE2COMPLETED
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery PHASE1COMPLETED
A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor PHASE1COMPLETED
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC PHASE1RECRUITING
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma PHASE1COMPLETED
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors PHASE1RECRUITING
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia PHASE1WITHDRAWN
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors PHASE1COMPLETED
Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies PHASE1COMPLETED
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response nanCOMPLETED
AusCADASIL: An Australian Cohort of CADASIL nanRECRUITING
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo nanRECRUITING
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches. nanRECRUITING
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma nanUNKNOWN
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases nanWITHDRAWN
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia nanCOMPLETED
Does Notch Regulate Glioma Proliferation ? nanCOMPLETED
MR Elastography in Intracranial Lesions: Feasibility & Accuracy nanACTIVE_NOT_RECRUITING
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury nanUNKNOWN
CADASIL Registry Study nanRECRUITING
Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls. nanUNKNOWN
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a NOTCH2 binder may also engage these)

ProteinNameSimilarity
Q9QW30 — 1.000 Q9QW30 →
NOTCH1 Neurogenic locus notch homolog protein 1 1.000 landscape →
O35516 — 1.000 O35516 →
G3I6Z6 — 0.999 G3I6Z6 →
P21783 — 0.997 P21783 →
Q01705 — 0.996 Q01705 →
P46530 — 0.995 P46530 →
Q07008 — 0.995 Q07008 →
Q9QXX0 — 0.991 Q9QXX0 →
A2RUV0 — 0.990 A2RUV0 →
P07207 — 0.990 P07207 →
P78504 — 0.987 P78504 →
Q5ZQU0 — 0.986 Q5ZQU0 →
B8JI71 — 0.986 B8JI71 →
Q63722 — 0.986 Q63722 →
Q9R172 — 0.984 Q9R172 →
Q7Z3S9 — 0.983 Q7Z3S9 →
Q90Y57 — 0.981 Q90Y57 →
Q61982 — 0.980 Q61982 →
A0A096LNW5 — 0.980 A0A096LNW5 →
P0DPK3 — 0.980 P0DPK3 →
Q90Y54 — 0.979 Q90Y54 →
O57409 — 0.978 O57409 →
P97607 — 0.977 P97607 →
Q70E20 — 0.977 Q70E20 →
NOTCH3 Neurogenic locus notch homolog protein 3 0.975 landscape →
O77469 — 0.975 O77469 →
Q8TER0 — 0.974 Q8TER0 →
Q8IWY4 — 0.974 Q8IWY4 →
O00548 — 0.974 O00548 →